Turning cancer resistance into vulnerability
Targeted Therapy for Relapsed & Refractory Cancers
We engineer small molecules designed to exploit metabolic vulnerabilities precisely when standard therapies fail.
Our Mission: Delivering cures for patients who have run out of options.
They support us
Our Technology - A metabolic trap
Cancer cells are addicted to proliferation and die when starved
Healthy cells simply pause and survive
Meet Our Complementary Team
Management Team
Guillaume Dubreuil
Co-founder & CEO
Guillaume Dubreuil
20+ years expertise inBusiness Development
Xavier Morelli
Co-founder & CSO
Xavier Morelli
CNRS Research Director (DRCE)25+ years expertise in Drug Discovery
Didier Pez
Co-founder & COO
Didier Pez
25+ years expertise inBiotech Drug Development
Name Placeholder
Co-founder & CCO
Name Placeholder
Driving commercial strategy and strategic partnerships to bring our precision therapeutics to patients globally.
Scientific Advisory Board
V. Asnafi
MD, PhD
Head of the Onco-Hematology laboratory and co-directs the "Normal and Pathological Lymphoid Differentiation Team" Institut Necker Enfants Malades
N. Vey
MD, PhD
Managing Director at the Institut Paoli-Calmettes (IPC), Professor of Hematology at Aix-Marseille University
C. Halfon-Domenech
MD, PhD
Head of the Pediatric immunohematology from Institut d’hématologie et d’oncologie pédiatrique (IHOPe)
F. Bellamy
PhD
Medicinal Chemistry and Preclinical Development within the pharmaceutical industry and start-up companies
P. Dubreuil
PhD
Doctor in Immunology Recognized expert in signal transduction pathways and kinase biology
The Science is Ready
- check_circleUnmet Need: Targeting refractory pediatric and adult ALL
- check_circleMode of Action: Metabolic synthetic lethality with high selectivity
- check_circleBridge-to-Transplant: Inducing rapid, MRD-negative remissions
The Business is Ready
- check_circleOrphan Strategy: Fast-to-market path for our lead asset (ORT001)
- check_circleCapital Efficient: Designed for rapid clinical validation and early exit
- check_circleSecured IP: Exclusive worldwide license (WO 2023/135330A1)
Let's transform the future of Leukemia
Investors, partners, and clinicians — let's build the future of precision oncology together.